Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

KEY TAKEAWAYS Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

mRESVIA is Moderna's second approved product in Canada ... has been granted a Drug ... ACCESSWIRE • 2 months ago EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion ...

"I don’t want to have a heart attack" by taking any more jabs, relatively young agency branch chief tells undercover date.

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...

STORY HIGHLIGHTS FDA approved BridgeBio's new heart disease treatment, Attruby. Attruby reduces hospitalizations and improves quality of life, according to the company. BridgeBio's stock rose over ...